COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,237 Articles (22,733 medRxiv, 8,504 bioRxiv)

Most recent first Previous |  Page 527: Articles 5261-5270  | Next

Bridging the gap_Estimation of 2022/2023 SARS-CoV-2 healthcare burden in Germany based on multidimensional data from a rapid epidemic panel
Harries, M., Jaeger, V., Rodiah, I., Hassenstein, M. J., Kurosinski, M. A., Ortmann, J., Dulovic, A., Gornyk, D., Schneiderhan-Marra, N., Kuczewski, C., Schlotz, M., Dreier, M., von Holt, I., Brinkmann, M., Hovardovska, O., Strengert, M., Krause, G., Sester, M., Klein, F., Petersmann, A., Karch, A., Lange, B.
10.1101/2022.12.30.22284061 — Posted: 2022-12-30
Estimated of expected COVID-19 deaths in Mainland China after abandoning zero COVID policy
Ioannidis, J. P. A., Zonta, F., Levitt, M.
10.1101/2022.12.29.22284048 — Posted: 2022-12-30
The kinetics of humoral and cellular responses after the booster dose of COVID-19 vaccine in inflammatory arthritis patients
Wronski, J., Jaszczyk, B., Roszkowski, L., Felis-Giemza, A., Bonek, K., Kornatka, A., Plebanczyk, M., Burakowski, T., Lisowska, B., Kwiatkowska, B., Maslinski, W., Wislowska, M., Massalska, M., Kuca-Warnawin, E., Ciechomska, M.
10.1101/2022.12.28.22284008 — Posted: 2022-12-30
Association between recent COVID-19 diagnosis on depression and anxiety symptoms among slum residents in Kampala, Uganda
Wafula, S. T., Ninsiima, L. R., Mendoza, H., Ssempebwa, J. C., Walter, F., Musoke, D.
10.1101/2022.12.28.22284012 — Posted: 2022-12-30
SARS-CoV-2 seroprevalence and longitudinal antibody response following natural infection in pregnancy
Drake, A., Escudero, J., Aurelio, M., Ellington, S., Zapata, L., Galang, R., Snead, M., Yamamoto, K., Salerno, C., Richardson, B., Greninger, A., Kachikis, A., Englund, J., LaCourse, S.
10.1101/2022.12.28.22284017 — Posted: 2022-12-30
Cost-effectiveness of the second COVID-19 booster vaccination in the United States
Li, R., Lu, P., Fairley, C. K., Pagan, J., Hu, W., Yang, Q., Zhuang, G., Shen, M., Li, Y., Zhang, L.
10.1101/2022.12.28.22283986 — Posted: 2022-12-30
Erythromycin, Retapamulin, Pyridoxine, Folic acid, and Ivermectin dose-dependently inhibit cytopathic effect, Papain-like Protease, and MPRO of SARS-CoV-2
Bello, S. O., Imam, M. U., Bello, M. B., Yunusa, A., Adamu, A. A., Shuaibu, A., Igumbor, E. U., Habib, Z. G., Popoola, M. A., Ochu, C. L., Bello, A. Y., Deeni, Y. Y., Okoye, I.
10.1101/2022.12.28.522082 — Posted: 2022-12-29
Cohort study of fever neonates with confirmed community infection of SARS-CoV-2 Omicron: A study Protocol
Li, J., He, W., Qi, Y., Meng, Y., Peng, X., Hei, M.
10.1101/2022.12.28.22283987 — Posted: 2022-12-29
SARS-CoV-2 accessory proteins ORF3a and ORF7a modulate autophagic flux and Ca2+ homeostasis in yeast
Garrido-Huarte, J. L., Fita-Torro, J., Viana, R., Pascual-Ahuir, A., Proft, M.
10.1101/2022.12.29.522217 — Posted: 2022-12-29
Immunogenicity of COVID-eVax Is Moderately Impacted by Temperature and Molecular Isoforms
D'Alessio, F., Lione, L., Salvatori, E., Bucci, F., Muzi, A., Roscilli, G., Conforti, A., Compagnone, M., Pinto, E., Battistuzzi, G., Aurisicchio, L., Palombo, F.
10.1101/2022.12.29.522202 — Posted: 2022-12-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).